Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

But the Galaxies Lung-201 trial features notable omissions, plus toxicity.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.